domingo, 11 de noviembre de 2018

Circulating plasma microRNAs as potential biomarkers of non-small cell lung cancer obtained by high-throughput real-time PCR profiling. - PubMed - NCBI

2018 Oct 30. pii: cebp.0723.2018. doi: 10.1158/1055-9965.EPI-18-0723. [Epub ahead of print]

Circulating plasma microRNAs as potential biomarkers of non-small cell lung cancer obtained by high-throughput real-time PCR profiling.

Niu Y1, Su M1, Wu Y1, Fu L2, Kang K3, Li Q1, Li L1, Hui G4, Li F5, Gou D6.

Author information

Abstract

BACKGROUND:

Because of limited stability and sensitivity, circulating miRNAs as noninvasive biomarkers has not so far been used for early diagnosis and prognosis of non-small cell lung cancer (NSCLC) in clinic. Therefore, it is still imperative to find more reliable biomarker(s).

METHODS:

We performed one of most sensitive RT-qPCR assays, S-Poly(T) Plus to selected differently expressed miRNAs from genome-wide miRNA profiling. miRNA candidates were validated through a three-phase selection and two-validation process with 437 NSCLC cases and 415 controls.

RESULTS:

A unique set of 7 and 9 miRNAs differed significantly in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) samples compared with those in controls, of which, there were 5 universal biomarkers for NSCLC (ADC or SCC). Ten out of eleven miRNAs could discriminate early stage (Stage I) of NSCLC from healthy individuals. Risk score was obtained from the validation set-1 and was tested using operating characteristic (ROC) curves with a high area under ROC curve of 0.89 in ADC and 0.96 in SCC. Ultimately, potential biomarkers and the risk score were verified by the validation set-2 with a sensitivity of 94% and a specificity of 91.6% in ADC, and a sensitivity of 98.5% and a specificity of 51.5% in SCC, respectively.